Retension Pharmaceuticals
MCLEAN, Virginia, United States · Biopharma, Biotechnology, Healthcare
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patien
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- MCLEAN, Virginia, United States
- Employees
- 10
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (RTSN)
- Website
- www.retensionpharmaceuticals.com
- Company page
Recent activity at Retension Pharmaceuticals
- : Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer
- : SEC 8-K (5.02): On October 21, 2026, Retension Pharmaceuticals, Inc. appointed Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026. Mr. Wong brings extensive experience, having held significant roles at companies like The Save Mart Companies and Cytokinetics, Inc. His compensation package includes an annual salary of $360,000, eligibility for a discretionary bonus, a sign-on bonus of $20,000, and a stock option award for 25,000 shares vested over four years. There was no predetermined arrangement for his appointment, ensuring organizational integrity in the hiring process.
- : Retension Pharmaceuticals Appoints LeAnne Bloedon as EVP of Clinical Development
About Retension Pharmaceuticals: questions and answers
What does Retension Pharmaceuticals do?
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patien
Where is Retension Pharmaceuticals headquartered?
Retension Pharmaceuticals is headquartered in MCLEAN, Virginia, United States.
How many employees does Retension Pharmaceuticals have?
Retension Pharmaceuticals has about 10 employees.
What is the latest news on Retension Pharmaceuticals?
On Oct 23, 2026, Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer
Is Retension Pharmaceuticals a public company?
Yes. Retension Pharmaceuticals is publicly traded under the ticker RTSN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy